First-Line Treatment Patterns of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) with and without BRAF Mutations in the US

被引：0
|
作者：
Vieira, M. Cecilia [1 ]
Duncan, K. [1 ]
Hsu, W. -C. [2 ]
Ross, R. [2 ]
Benjumea, D. [2 ]
Vlahiotis, A. [1 ]
Li, B. [1 ]
Wilner, K. D. [3 ]
机构：
[1] Pfizer Inc, New York, NY USA
[2] Genesis Res LLC, Hoboken, NJ USA
[3] Pfizer Inc, San Diego, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.61
引用
收藏
页码：E36 / E36
页数：1
相关论文
共 50 条
  • [41] Prediction of Response to First Line Treatment for Metastatic Non-Small Cell Lung Cancer
    Badawy, Ahmed
    Khedr, Gehan
    Arafat, Waleed
    Bae, Sejong
    Omar, Abbas
    Grant, Stefan
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S908 - S908
  • [42] Treatment (Tx) inequities in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) harboring actionable driver oncogenes (ADO) in the first-line (1L) setting
    Vidal, Gregory A.
    Stricker, Thomas
    Ma, Esprit
    Yu, Elaine
    Xia, Zhiyu
    Sheinson, Daniel
    Sincan, Murat
    Huang, Richard S. P.
    Lin, Victor T. G.
    Zuniga, Richard Michael
    Jain, Neha M.
    Martin, Richard Lewis
    Daniel, Davey B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer
    Spence, Michele M.
    Hui, Rita L.
    Chang, Jennifer T.
    Schottinger, Joanne E.
    Millares, Mirta
    Rashid, Nazia
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (02): : 159 - 159
  • [44] Cost-effectiveness of atezolizumab monotherapy versus pembrolizumab monotherapy for first-line (1L) treatment of metastatic non-small cell lung cancer (mNSCLC).
    Lin, Chia-Wei
    Rosettie, Katherine
    Bilir, Pinar
    Celik, Hazal
    Abogunrin, Seye
    Ogale, Sarika
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] First-Line Treatment of Driver-Negative Non-Small Cell Lung Cancer
    Kim, So Yeon
    Gettinger, Scott
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (03) : 557 - 573
  • [46] Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer
    Montalar, J
    Morales, S
    Maestu, I
    Camps, C
    Vadell, C
    García, R
    Yuste, AL
    Torregrosa, D
    Segura, A
    LUNG CANCER, 2001, 34 (02) : 305 - 311
  • [47] Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer
    Chang, Myung Hee
    Kim, Kyoung Ha
    Jun, Hyun Jung
    Kim, Hyo Song
    Yi, Seong Yoon
    Uhm, Ji Eun
    Park, Min Jae
    Lim, Do Hyoung
    Ji, Sang Hoon
    Hwang, In Gyu
    Lee, Jeeyun
    Park, Yeon Hee
    Ahn, Jin Seok
    Ahn, Myung-ju
    Park, Keunchil
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (05) : 917 - 924
  • [48] Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer
    Li, Tianhong
    Ma, Weijie
    Al-Obeidi, Ebaa
    CANCERS, 2024, 16 (13)
  • [49] Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer
    Myung Hee Chang
    Kyoung Ha Kim
    Hyun Jung Jun
    Hyo Song Kim
    Seong Yoon Yi
    Ji Eun Uhm
    Min Jae Park
    Do Hyoung Lim
    Sang Hoon Ji
    In Gyu Hwang
    Jeeyun Lee
    Yeon Hee Park
    Jin Seok Ahn
    Myung-ju Ahn
    Keunchil Park
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 917 - 924
  • [50] What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?
    Ricciuti, Biagio
    Awad, Mark M.
    CANCER JOURNAL, 2020, 26 (06): : 485 - 495
12345